地中海贫血合并自身或同种异体抗体的研究进展  

Research Progress of Thalassemia Combined with Autoantibodies or Allogeneic Antibodies

作　　者：李静 陈要朋 唐卒卒 尹晓林 LI Jing;CHEN Yaopeng;TANG Zuzu;YIN Xiaolin(The 923th Hospital of the Joint Logistics Support Force of Chinese People's Liberation Army,Nanning 530021,China;不详)

机构地区：[1]中国人民解放军联勤保障部队第九二三医院,广西南宁530021

出　　处：《中外医学研究》2024年第2期181-184,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：广西卫生健康委员会科研课题项目(Z20211228,Z-A20231087)。

摘　　要：地中海贫血是一种严重的进行性贫血,需要规范化输血和祛铁才能达到预期寿命。输血最重要的并发症之一是同种异体免疫和自身免疫,增加了配血的难度,也降低了输血的效果。本文综述了地中海贫血合并自身免疫性溶血性贫血(AIHA)的发生率、诊断及临床特点、输血及药物治疗现状,并对红细胞寿命(RBCS)检测的方法及在地中海贫血合并AIHA中的应用可行性进行了分析。Thalassemia is a severe progressive anemia that requires regular blood transfusion and iron chelator to reach life expectancy.One of the most important complications of blood transfusion is alloimmunity and autoimmunity,which increases the difficulty of blood matching and reduces the effect of blood transfusion.This article reviewed the incidence,diagnosis and clinical characteristics,blood transfusion and drug treatment of patients with thalassemia complicated with autoimmune hemolytic anemia,and analyzed the feasibility of red blood cell life span(RBCS)testing methods and their application in the patients with thalassemia complicated with autoimmune hemolytic anemia.

关 键 词：地中海贫血 自身免疫性溶血性贫血 红细胞寿命 

分 类 号：R556.61[医药卫生—血液循环系统疾病]